Risultati per: L’arma segreta dell’olio d’oliva contro l’Alzheimer: i composti fenolici

Un nuovo studio suggerisce che il primo farmaco Glp-1 impiegato per combattere diabete e obesità, può ridurre la perdita di massa cerebrale

Lo conferma uno studio su 1.200 persone

This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.

Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Volume 390, Issue 23, Page 2156-2164, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2212-2213, June 20, 2024.

New England Journal of Medicine, Volume 390, Issue 23, Page 2217-2219, June 20, 2024.

This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.

I consulenti dell’Fda hanno approvato il farmaco di Eli Lilly. Entro la fine dell’anno si attende l’ok definitivo da parte dell’Ente regolatorio

Su Nature uno studio spagnolo suggerisce che quasi tutti coloro che hanno due copie della variante genetica ApoE4 sviluppano la malattia

Sorgerà all’interno di un parco pubblico

La mutazione aumenta l’abilità del cervello di ripulirsi

This finding strengthens the case for early targeting of amyloid-β42 in people at excess risk for AD.